Molecure Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Marcin Szumowski

Amministratore delegato

zł473.2k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	0.7%
Durata media del management	3.8yrs
Durata media del Consiglio di amministrazione	2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Marcin Szumowski

no data

Mandato

zł473,205

Compensazione

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Marcin Szumowski	Co-Founder	no data	zł473.21k	0.70% € 281.3k
Slawomir Broniarek	CFO & Member of the Management Board	no data	zł421.09k	0.20% € 82.8k
Zbigniew Zaslona	Chief Scientific Officer & Member of Management Board	2.8yrs	zł473.21k	0.11% € 45.3k
Agnieszka Rajczuk-Szczepanska	Member of Management Board & HR Director	4.8yrs	zł348.41k	0.034% € 13.9k
Adam Golebiowski	Co-Founder & VP of Research Chemistry	12.8yrs	zł500.00k	3.01% € 1.2m
Jacek Olczak	Co-Founder & Head of Medicinal Chemistry	no data	Nessun dato	Nessun dato
Piotr Iwanowski	Chief Medical Officer & Member of Management Board	less than a year	Nessun dato	Nessun dato
Magdalena Tyszkiewicz	Head of CMC	4.8yrs	Nessun dato	Nessun dato
Marta Borkowska	Director of the Management Board Office	2.8yrs	Nessun dato	Nessun dato

3.8yrs

Durata media

Gestione esperta: Il team dirigenziale di 1B1 è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Luke O'Neill	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Bart Lambrecht	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Tomasz Piec	Vice Chairman of the Supervisory Board	4.8yrs	zł133.62k	Nessun dato
Douglas Hay	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Paul Van Der Horst	Independent Chairman of the Supervisory Board	2.8yrs	zł132.99k	0.059% € 24.0k
Nancy Van Osselaer	Independent Member of the Supervisory Board	2.8yrs	zł124.22k	Nessun dato
Agnieszka Motyl	Member of the Supervisory Board	1.3yrs	zł44.45k	Nessun dato
Pawel Trawkowski	Independent Member of the Supervisory Board	2.4yrs	zł124.22k	Nessun dato

2.8yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 1B1 non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.

Molecure Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Molecure S.A., Annual General Meeting, Jun 13, 2024

Molecure S.A., Annual General Meeting, May 31, 2023

Molecure S.A. Announces Management Changes

Molecure S.A., Annual General Meeting, Jun 30, 2022

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

Recent updates

New minor risk - Profitability

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Molecure S.A., Annual General Meeting, May 31, 2023

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media